Added to YB: 2026-04-02
Pitch date: 2026-02-12
PGEN [bullish]
Precigen, Inc.
-17.95%
current return
Author Info
No bio for this author
Company Info
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Market Cap
$1.2B
Pitch Price
$4.79
Price Target
24.00 (+520%)
Dividend
N/A
EV/EBITDA
-11.35
P/E
-2.37
EV/Sales
118.82
Sector
Biotechnology
Category
growth
Precigen, Inc. - $PGEN
PGEN: Biotech w/ Papzimeous approved Aug 2025 for RRP (27K US patients). $460K/treatment 'one & done' at $92K net/dose. Early launch phase getting reimbursement/hospital approvals. Est 1,744 patients treated in 2026 vs mkt expectations 4-5x lower. Q1 rev beat 100%+, Q2 300%+ beat should drive stock 2-3x. Forecasting Q2 GAAP profitability. Targets 1,644 patients 2026, 9,356 over 4yrs (35% penetration). NPV model + PE analysis = $18-24 PT. Merck likely acquirer at $20/share by mid-2027. Ex-US expansion + anogenital warts opportunity adds upside.
Read full article (10 min)